All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 195 points (-1.1%) at 16,964 as of Wednesday, Jan. 6, 2016, 11:55 AM ET. The NYSE advances/declines ratio sits at 842 issues advancing vs. 2,118 declining with 157 unchanged.

The Health Care sector currently sits down 1.1% versus the S&P 500, which is down 0.7%. Top gainers within the sector include Valeant Pharmaceuticals International ( VRX), up 3.1%, Regeneron Pharmaceuticals ( REGN), up 2.4%, Hologic ( HOLX), up 1.9%, Gilead ( GILD), up 1.2% and Illumina ( ILMN), up 0.9%. On the negative front, top decliners within the sector include ACADIA Pharmaceuticals ( ACAD), down 12.9%, Endo International ( ENDP), down 2.0%, Shire ( SHPG), down 1.9%, Sanofi ( SNY), down 1.4% and Anthem ( ANTM), down 1.3%.

TheStreet would like to highlight 3 stocks pushing the sector higher today:

3. PRA Health ( PRAH) is one of the companies pushing the Health Care sector higher today. As of noon trading, PRA Health is up $3.10 (7.0%) to $47.09 on heavy volume. Thus far, 211,309 shares of PRA Health exchanged hands as compared to its average daily volume of 270,400 shares. The stock has ranged in price between $43.13-$47.53 after having opened the day at $43.43 as compared to the previous trading day's close of $43.99.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

PRA Health Sciences, Inc., a contract research organization, provides various product development services for pharmaceutical and biotechnology companies worldwide. PRA Health has a market cap of $2.7 billion and is part of the health services industry. Shares are down 2.8% year-to-date as of the close of trading on Tuesday. Currently there are 4 analysts who rate PRA Health a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates PRA Health as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth and impressive record of earnings per share growth. However, as a counter to these strengths, we also find weaknesses including generally higher debt management risk and poor profit margins. Get the full PRA Health Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading, Alexion Pharmaceuticals ( ALXN) is up $2.02 (1.1%) to $186.92 on light volume. Thus far, 341,931 shares of Alexion Pharmaceuticals exchanged hands as compared to its average daily volume of 1.3 million shares. The stock has ranged in price between $183.03-$186.92 after having opened the day at $183.51 as compared to the previous trading day's close of $184.90.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. Alexion Pharmaceuticals has a market cap of $41.6 billion and is part of the drugs industry. Shares are down 3.1% year-to-date as of the close of trading on Tuesday. Currently there are 12 analysts who rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Alexion Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full Alexion Pharmaceuticals Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading, Perrigo ( PRGO) is up $2.02 (1.4%) to $144.70 on average volume. Thus far, 1.1 million shares of Perrigo exchanged hands as compared to its average daily volume of 2.2 million shares. The stock has ranged in price between $141.00-$144.86 after having opened the day at $141.20 as compared to the previous trading day's close of $142.68.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Perrigo Company plc, through its subsidiaries, develops, manufactures, and markets over-the-counter (OTC) consumer goods and pharmaceutical products worldwide. Perrigo has a market cap of $20.9 billion and is part of the drugs industry. Shares are down 1.4% year-to-date as of the close of trading on Tuesday. Currently there are 8 analysts who rate Perrigo a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Perrigo as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, disappointing return on equity and weak operating cash flow. Get the full Perrigo Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).